Several studies revealed that different strategies for NAFLD treatment were related to the activation of the AMPK/mTOR/SREBP1c signaling pathway [43,44,45,46]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.